Clinical trial
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast…
NCT00422903 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00422903 |
|---|---|
| Title | Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer |
| Official title | Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug, Other |
| Interventions | lapatinib, letrozole, placebo |
| Enrollment | 92 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Jan 17, 2007 |
| Last update posted | May 12, 2016 |
| Countries | Italy, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: